Prothena Corporation plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Prothena Corporation plc
FDA guidances have provided ‘major step forward’ for use of social media data, Roche researcher notes. Agency staffer offers checklist for collecting patient experience data in this realm.
Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.
Novartis and Roche may be committed to the target, but AbbVie has decided that its efforts in Parkinson's will not include a Phase II trial of its Swedish partner's alpha synuclein drug.
ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.
- Large Molecule
- Other Names / Subsidiaries
- Neotope Biosciences Limited